Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
NCT06326021Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FL-33 in acute myeloid leukemia (AML) (4 arms), sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 21 days and Adverse events at 30 days. Started Apr 2024; status: recruiting.
02
Drugs
FL-33
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06326021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326021.